[Ip-health] Economic genocide

George Carter gmcfiar at gmail.com
Sun Feb 1 11:37:18 PST 2015

Once again, profit trumps life! 
I knew Modi would be a sycophantic shill for cash. It is what one might expect from a cheesy fundamentalist.
George M. Carter

Delhi high court sets aside India patent office rejection of Sovaldi patent • 2:29 PM
Douglas W. House, SA News Ed...
On procedural grounds, the Delhi high court sets aside the recent decision by the Deputy Controller of Patents and Design rejecting Gilead Sciences' (NASDAQ:GILD) patent application for its HCV drug Sovaldi.
The patent office rejected Gilead's submission on the basis of Section 3(d) of the Patents Act which prevents evergreening of patents and states that a new version of an existing substance cannot be patented unless it is much more effective than the old version. Its position was that sofosbuvir represented a minor change to an existing molecule that did not deliver improved efficacy.
India legal experts believed that the company's appeal would succeed because the reasoning in the controller's order was slipshod. The procedural misconduct occurred in the pre-grant opposition stage of the application review. This is the point where the reviewer examines information submitted by opposing parties before a final ruling is issued. Under Indian law, the office was required to notify Gilead, which it did not . Also, the controller maintained that he did not rely on claims made in the pre-grant opposition, but certain sections of the order appeared strikingly similar to parts of the opposition application from Indian generic firm Natco Pharma Ltd. Justice Rajiv Shakdher said the it appeared that patent office "generously took assistance from the material" filed by the opponents.
A written order has not yet been issued by the high court but it stated that an order by the patent office cannot be passed without every opposing party being heard. In Sovaldi's case, there are four oppositions so additional review is required before a final ruling can be made.
Previously: Gilead to fight ruling from India patent office (Jan. 16)
Previously: India patent office slaps Gilead in the face (Jan. 14)
Read comments
GILD price at time of publication: $104.83. Check GILD price now »

Was this email forwarded to you? Learn more about Seeking Alpha Alerts here »

Focus Articles on GILD
Can Gilead Beat AbbVie At Its Own Game? by Kanak Kanti De
What Lessons Has Express Scripts Taught Us? The Future For The Pharmaceutical Industryby Pharma Doc
50% Upside For Gilead In 2015 by Phoenician
More News on GILD
FDA clears Janssen's HIV-1 combo pill Jan 30, 7:39 AM ET (Seeking Alpha)
Cramer's guide to a treacherous trader's market Jan 13, 6:14 PM ET (CNBC)
Health care's strong 2015 outlook Jan 13, 12:45 PM ET (CNBC)
Press Releases on GILD
Gilead Announces Executive Promotions (Business Wire)
Gilead Sciences to Release Fourth Quarter and Full Year 2014 Financial Results on Tuesday, February 3, 2015 (Business Wire)
Gilead Expands Hepatitis C Generic Licensing Agreements to Include Investigational Pan-Genotypic Agent (Business Wire)
Related Articles on GILD
Amgen Offers Impressive Upside As A New Product Cycle Begins by Alexander J. Poulos
Seeking Alpha's Biotech Weekly: Intercept Pops, Provenge's Prince Valeant, And More by SA Editor Mike Taylor
The 2015 Calendar Of NASH Trial Catalysts: Intercept's Breakthrough Designation Hastens Decision Process by Clinically Sound Investor
StockTalk on GILD: GILD StockTalk | Twitter GILD | Twitter $GILD | GILD Instablogs

Recent Market Alerts on GILD: All news | Earnings | Dividends | M&A | On the move

Transcripts on GILD
Gilead Sciences' (GILD) Management Presents at Piper Jaffray Healthcare Conference (Transcript) by SA Transcripts
Gilead Sciences' (GILD) CEO John Martin on Q3 2014 Results - Earnings Call Transcript by SA Transcripts
Gilead Sciences (GILD) Q3 2014 Results - Earnings Call Webcast by SA Transcripts
Early Look at tomorrow’s key articles ($30)

Subscribers currently have exclusive early access to 37 articles.

Subscribe Now »
This email was sent to fiar at verizon.net by Seeking Alpha.
Seeking Alpha, 52 Vanderbilt Avenue, 13th floor, New York, NY 10017

More information about the Ip-health mailing list